0.645
0.01 (1.78%)
| Penutupan Terdahulu | 0.634 |
| Buka | 0.640 |
| Jumlah Dagangan | 340,665 |
| Purata Dagangan (3B) | 930,837 |
| Modal Pasaran | 31,298,722 |
| Harga / Jualan (P/S) | 10.21 |
| Harga / Buku (P/B) | 1.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -6,511.20% |
| EPS Cair (TTM) | -1.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 64.59% |
| Nisbah Semasa (MRQ) | 8.10 |
| Aliran Tunai Operasi (OCF TTM) | -59.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.80 M |
| Pulangan Atas Aset (ROA TTM) | -32.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -82.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Werewolf Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.07% |
| % Dimiliki oleh Institusi | 62.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mpm Asset Management Llc | 30 Sep 2025 | 4,309,860 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 7.00 (B of A Securities, 985.61%) | Beli |
| Median | 5.50 (752.98%) | |
| Rendah | 4.00 (HC Wainwright & Co., 520.35%) | Beli |
| Purata | 5.50 (752.98%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.801 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Dec 2025 | 4.00 (520.35%) | Beli | 0.687 |
| B of A Securities | 18 Nov 2025 | 7.00 (985.61%) | Beli | 0.915 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2025 | Pengumuman | Werewolf Therapeutics Announces Pipeline and Business Updates |
| 07 Nov 2025 | Pengumuman | Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting |
| 04 Nov 2025 | Pengumuman | Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |